Umeå universitets logga

umu.sePublikationer
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Surrogate measures of first-phase insulin secretion versus reference methods intravenous glucose tolerance test and hyperglycemic clamp: a systematic review and meta-analyses
Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin.
Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin.
German Center for Diabetes Research (DZD), Neuherberg, Germany; Department of Internal Medicine IV, Division of Diabetology, Endocrinology and Nephrology, Eberhard-Karls University Tübingen, Tübingen, Germany; Department for Diagnostic Laboratory Medicine, Institute for Clinical Chemistry and Pathobiochemistry, University Hospital of Tübingen, Tübingen, Germany.
German Center for Diabetes Research (DZD), Neuherberg, Germany; Department of Internal Medicine IV, Division of Diabetology, Endocrinology and Nephrology, Eberhard-Karls University Tübingen, Tübingen, Germany; Institute for Diabetes Research and Metabolic Diseases, Helmholtz Center Munich, University of Tübingen, Tübingen, Germany.
Visa övriga samt affilieringar
2024 (Engelska)Ingår i: BMJ Open Diabetes Research & Care, ISSN 2052-4897, Vol. 12, nr 4, artikel-id e004256Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Introduction: In this systematic review, we investigated the diagnostic accuracy of surrogate measures of insulin secretion based on fasting samples and the oral glucose tolerance test (OGTT). The first phase of insulin secretion was calculated using two gold standard methods; the hyperglycemic clamp (HGC) test and intravenous glucose tolerance test (IVGTT).

Research design and methods: We conducted searches in the PubMed, Cochrane Central, and Web of Science databases, the last of which was conducted at the end of June 2021. Studies were included that measured first-phase insulin secretion in adults using both a gold-standard reference method (either HGC or IVGTT) and one or more surrogate measures from either fasting samples, OGTT or a meal-tolerance test. QUADAS-2, a revised tool for the quality assessment of diagnostic accuracy studies, was used for quality assessment. Random-effects meta-analyses were performed to examine the correlation between first-phase measured with gold standard and surrogate methods.

Results: A total of 33 articles, encompassing 5362 individuals with normal glucose tolerance, pre-diabetes or type 2 diabetes, were included in our systematic review. Homeostatic model assessment (HOMA)-beta and Insulinogenic Index 30 (IGI(30)) were the surrogate measures validated in the largest number of studies (17 and 13, respectively). HOMA-beta's pooled correlation to the reference methods was 0.48 (95% CI 0.40 to 0.56) The pooled correlation of IGI to the reference methods was 0.61 (95% CI 0.54 to 0.68). The surrogate measures with the highest correlation to the reference methods were Kadowaki (0.67 (95% CI 0.61 to 0.73)) and Stumvoll's first-phase secretion (0.65 (95% CI 0.58 to 0.71)), both calculated from an OGTT.

Conclusions: Surrogate measures from the first 30 min of an OGTT capture the first phase of insulin secretion and are a good choice for epidemiological studies. HOMA-beta has a moderate correlation to the reference methods but is not a measure of the first phase specifically.

Ort, förlag, år, upplaga, sidor
BMJ Publishing Group Ltd, 2024. Vol. 12, nr 4, artikel-id e004256
Nationell ämneskategori
Endokrinologi och diabetes
Identifikatorer
URN: urn:nbn:se:umu:diva-228067DOI: 10.1136/bmjdrc-2024-004256ISI: 001311637200001PubMedID: 39013634Scopus ID: 2-s2.0-85199014679OAI: oai:DiVA.org:umu-228067DiVA, id: diva2:1886432
Forskningsfinansiär
Region VästerbottenTillgänglig från: 2024-08-01 Skapad: 2024-08-01 Senast uppdaterad: 2026-04-29Bibliografiskt granskad
Ingår i avhandling
1. Type 2 diabetes: from insulin dynamics to eHealth: new pathways for early diagnosis and treatment
Öppna denna publikation i ny flik eller fönster >>Type 2 diabetes: from insulin dynamics to eHealth: new pathways for early diagnosis and treatment
2026 (Engelska)Doktorsavhandling, sammanläggning (Övrigt vetenskapligt)
Abstract [en]

Type 2 diabetes (T2D) is one of the most rapidly increasing metabolic diseases worldwide, affecting more than 500 million individuals. The condition is characterized not only by chronic hyperglycemia but also bya long preceding phase of metabolic dysregulation. Before glucose levels reach diagnostic thresholds, most individuals experience a period of prediabetes with insulin resistance and compensatory elevations in both insulin secretion and circulating insulin levels. This stage is far from benign: prediabetes is associated with an increased risk of cardiovascular disease, neuropathy, and renal impairment. Understanding the mechanisms that drive these early metabolic changes is therefore important for improving prevention and treatment strategies. Central components in the development of prediabetes are insulin secretion, insulin clearance, and insulin sensitivity. Despite their importance, these processes are challenging to measure accurately in large populations and their respective contributions to early cardiometabolic disease remain incompletely understood. This thesis aims to deepen our understanding of insulin dynamics in prediabetes through four complementary studies.

The first study addressed how to measure first-phase insulin secretion reliably in large-scale research. By conducting meta-analyses of published studies comparing gold-standard methods of insulin secretion with commonly used surrogate measures, we evaluated the validity of these surrogate measures and provide guidance for their use in epidemiological settings. In total, 33 studies comprising 5362 participants with normal glucose tolerance, prediabetes, or T2D were included. Among surrogate measures evaluated, those derived from the first 30 min of the oral glucose tolerance test (OGTT) most closely approximated gold-standard measures of first-phase insulin secretion.

The second study examined how insulin secretion is reflected in the metabolic signature in individuals with prediabetes. By comparing individuals with prediabetes and high insulin secretion, prediabetes withlow secretion, normal glucose tolerance, and T2D, we investigated metabolic differences in plasma samples collected during an OGTT. Plasma samples from 100 participants were obtained at 0 and 120 min during the OGTT, and 280 metabolites and 218 putative lipids were quantified using ultra-high performance liquid chromatography quadrupole time-of-flight mass spectrometry. Classification models identified key metabolites and lipids distinguishing the four groups, including ceramides. Notably, the ratio of Cer(d18:1/24:1) toCer(d18:1/24:0), which has been associated with cardiovascular risk, was highest in the prediabetes group with high insulin secretion.

The third study investigated the role of insulin dynamics in the development of atherosclerosis in a population without diabetes. By examining correlations between insulin secretion, insulin clearance, and insulin sensitivity on the one hand, and subclinical atherosclerosis in coronary and carotid arteries on the other, we explored how early metabolic disturbances contribute to atherosclerotic cardiovascular disease. A total of 2054 individuals 50–64 years of age were included. Insulin dynamics were assessed using an OGTT and atherosclerosis using computed tomography of the coronary arteries and ultrasound of both carotid arteries. Our findings indicate that increased insulin resistance is associated with early atherosclerotic changes, even after adjustment for cardiovascular risk factors.

The fourth study shifts focus from pathophysiology to clinical management, exploring how digital health interventions can support individuals with T2D in achieving remission. Diabetes remission can be achieved through substantial weight loss. Participants in this study followed a low-calorie diet for 3 months, after which they gradually reintroduced food to support weight maintenance. They were monitored through digital meetings and self-reported body weight and blood glucose on a digital platform. In this study, we examined participants’ experiences of this eHealth-supported intervention using interviews analyzed with qualitative content analysis. Ten participants with more than 1 year’s experience of eHealth support for weight loss were interviewed. The results highlighted both empowering aspects, such as increased autonomy, and challenges, such as feelings of isolation and communication barriers.

The use of validated surrogate measures enables the estimation of insulin secretion in large populations. Looking ahead, these measures, combined with lipid profiling may contribute to more person-centeredcare by helping to identify individuals at elevated risk of future cardiovascular disease. Furthermore, our finding that insulin resistance is associated with early atherosclerosis underscores the need for early risk identification to provide preventive interventions. To enable broad implementations of such strategies, resource-efficient solutions are essential, which we explored in our final study.

Ort, förlag, år, upplaga, sidor
Umeå: Umeå University, 2026. s. 72
Nyckelord
prediabetes, insulin dynamics, insulin resistance, insulin secretion, metabolomics, atherosclerosis, digital health interventions
Nationell ämneskategori
Endokrinologi och diabetes
Identifikatorer
urn:nbn:se:umu:diva-252633 (URN)978-91-8070-948-4 (ISBN)978-91-8070-947-7 (ISBN)
Disputation
2026-05-29, Bergasalen, Norrlands universitetssjukhus, Umeå, 09:00 (Svenska)
Opponent
Handledare
Tillgänglig från: 2026-05-08 Skapad: 2026-04-29 Senast uppdaterad: 2026-05-04Bibliografiskt granskad

Open Access i DiVA

fulltext(943 kB)186 nedladdningar
Filinformation
Filnamn FULLTEXT01.pdfFilstorlek 943 kBChecksumma SHA-512
b222899905a48df1c1308eaa7c69b9b685be60f9d986f7ece1bf3aefcf42e8025c1f070f4978d240857bdf44bea5aa19294f56c91916279c2dd3079117bb3d47
Typ fulltextMimetyp application/pdf

Övriga länkar

Förlagets fulltextPubMedScopus

Person

Renklint, RebeckaChninou, YoussefOtten, Julia

Sök vidare i DiVA

Av författaren/redaktören
Renklint, RebeckaChninou, YoussefOtten, Julia
Av organisationen
Institutionen för folkhälsa och klinisk medicin
I samma tidskrift
BMJ Open Diabetes Research & Care
Endokrinologi och diabetes

Sök vidare utanför DiVA

GoogleGoogle Scholar
Totalt: 188 nedladdningar
Antalet nedladdningar är summan av nedladdningar för alla fulltexter. Det kan inkludera t.ex tidigare versioner som nu inte längre är tillgängliga.

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 421 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf